Comment by 5440

For those of you in FDA regulated devices, my clients started receiving FDA NSE letters for not performing fuzz testing. For example, "Though you have provided penetration testing, it does not appear that you have addressed the other items identified such as static and dynamic code analysis, malformed input (fuzz) testing, or vulnerability scanning. This testing is necessary to assess the effectiveness of the cybersecurity controls implemented and to determine whether the residual risk of your device is acceptable."